医学
接种疫苗
人乳头瘤病毒疫苗
dna疫苗
人乳头瘤病毒
传输(电信)
造谣
生殖道
心理干预
免疫学
生殖器疣
HPV感染
宫颈癌
免疫
癌症
内科学
免疫系统
社会化媒体
生理学
精神科
政治学
法学
电气工程
工程类
出处
期刊:Clinical Obstetrics and Gynecology
[Ovid Technologies (Wolters Kluwer)]
日期:2023-07-25
卷期号:66 (3): 433-447
标识
DOI:10.1097/grf.0000000000000788
摘要
Human papillomavirus (HPV) vaccines are highly effective in preventing the transmission of HPV and thus downstream HPV-related lower genital tract neoplasias. First introduced in 2006, the HPV vaccine has demonstrated clinical efficacy in both men and women. Several commercially available vaccines now exist, but only one is available in the United States. Both prelicensure and postlicensure studies demonstrate robust safety profiles. HPV vaccines should be made available to everyone between the ages of 9 and 26 years of age. Newer vaccination recommendations in expanded populations rely on patient-provider shared decision making. Currently, available HPV vaccines offer little therapeutic benefit. Recent research has identified several new DNA vaccines and delivery modifications with early demonstrated success at eliminating prevalent HPV infections and precancerous lesions. Despite the success of the HPV vaccine, vaccination hesitancy and disinformation continue to threaten our ability to eliminate these deadly cancers. Informational, behavioral, and environmental interventions have mixed success in increasing vaccination rates, but several strategies do exist to increase rates of vaccination.
科研通智能强力驱动
Strongly Powered by AbleSci AI